Expenditures for research and development intended to lead to new products of commercial value:
A. Should be recorded as intangible assets and amortized during the years in which benefits are expected.
B. Should be charged to expense when incurred.
C. Should be capitalized only if patents are expected to be granted.
D. Should be classified as deferred charges.